ClinicalTrials.gg
TerminatedNCT06972953Updated Nov 17, 2026

NEUROvascular NAVigation With Remotely Controlled Deflectable Guidewire, Study I (NeuroNAV Study I)

An interventional study of SmartGUIDE (deflectable guidewire) and Any standard of care guidewire in Unruptured Cerebral Aneurysm, sponsored by Artiria Medical. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Artiria Medical · Not applicable, Interventional, and Other

How we know

Why this study was terminated
The study was prematurely terminated following the successful EU CE marking of the device, which rendered the continuation of the investigation unnecessary. The study was not terminated for reasons related to participants' safety.
Updated Nov 17, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.

Enrollment
23rd of 23
6 · median 171
Started
2025
with 3 others
No phase
18 of 66
8 open now
Registered
61st of 66
by date

Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 with no phase, and was the 61st registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Intracranial Aneurysm with a site in France, or all of them as a file.
02

Study summary

The aim of the study is to confirm the safe and successful use of the SmartGUIDE guidewire, when used in neuro interventions. The performance of the SmartGUIDE guidewire in terms of safe and successful navigation within the neurovasculature will be compared to standard of care guidewire on the market.

03

Conditions studied

  • Unruptured Cerebral Aneurysm

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years of age
  • signed by the patient
  • Confirmed cerebral unruptured aneurysm treatable via transcatheter approach

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Known disorder of vascular fragility with propensity to vascular injury (e.g., Ehlers-Danlos syndrome)
  • Known prior vascular stenosis or dissection or injury to vessels intended to be catheterized during study procedures
  • Acute phase myocardial infarction or uncontrolled cardiac arrhythmia
  • Uncontrolled serum electrolyte imbalance
  • Bleeding disorder which limits the use of antiplatelet and/or anticoagulant therapy
  • Known to intravascular contrast material that cannot be adequately controlled with pre-medication
  • Known to Nickel
  • Subjects currently enrolled in another device or drug study that clinically interferes with the current study endpoints
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    SmartGUIDE (deflectable guidewire)

    Device: SmartGUIDE (deflectable guidewire)

  • Active comparator
    Any standard of care guidewire

    Device: Any standard of care guidewire

Interventions

  • DeviceSmartGUIDE (deflectable guidewire)

    SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.

  • DeviceAny standard of care guidewire

    The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.

06

What researchers measure

Primary outcomes

  1. Performance

    Intra-procedural technical success defined as successful navigation of device to the target vessel without need for shaping by hand, removal or exchange.

    Time frame: During index procedure

Secondary outcomes

  1. Usability

    Usability data (shape retention, pushability, trackability, navigability, support, proximal access complexity) collected through questionnaire.

    Time frame: During index procedure

  2. Procedural times

    Procedural times (duration of tip reshaping, duration of access to target, duration of fluoroscopic exposition).

    Time frame: During index procedure

  3. Intra-procedural adverse events

    Occurrence of adverse events.

    Time frame: During index procedure and up to 48 hours post procedure

  4. Intra-procedural device deficiencies

    Occurrence of intra-procedural device deficiencies.

    Time frame: During index procedure

07

Study locations

1 site
  • Centre Hospitalier Universitaire - CHU Limoges
    Limoges, 87042, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Jul 2026, 13 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2026 → Jul 2026 and completion Dec 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 15, 2025
StartActual
Jun 16, 2025
Primary completionActual
Jul 17, 2026was Dec 2026
CompletionActual
Jul 17, 2026was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The study was prematurely terminated following the successful EU CE marking of the device, which rendered the continuation of the investigation unnecessary. The study was not terminated for reasons related to participants' safety.
changed Nov 17, 2026
Primary completion
Dec 2026→Jul 17, 2026 (actual)
Nov 17, 2026
Study completion
Dec 2026→Jul 17, 2026 (actual)
Nov 17, 2026
Enrollment
30 (estimated)→6 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Terminated
    Why stopped The study was prematurely terminated following the successful EU CE marking of the device, which rendered the continuation of the investigation unnecessary. The study was not terminated for reasons related to participants' safety.
    Primary completion Dec 2026→Jul 17, 2026 (now actual)
    Study completion Dec 2026→Jul 17, 2026 (now actual)
    Enrollment 30 (estimated)→6 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06972953
Lead sponsor
Artiria Medical
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Jun 16, 2025
Primary completion
Jul 17, 2026
Completion
Jul 17, 2026
Last update
Nov 17, 2026

Study contacts

Prof. Dr. Aymeric Rouchaud
principal investigator · Centre Hospitalier Universitaire - CHU Limoges

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion